EP0527063A1 - Production of protein of interest in the milk of transgenic mammal - Google Patents

Production of protein of interest in the milk of transgenic mammal Download PDF

Info

Publication number
EP0527063A1
EP0527063A1 EP92401635A EP92401635A EP0527063A1 EP 0527063 A1 EP0527063 A1 EP 0527063A1 EP 92401635 A EP92401635 A EP 92401635A EP 92401635 A EP92401635 A EP 92401635A EP 0527063 A1 EP0527063 A1 EP 0527063A1
Authority
EP
European Patent Office
Prior art keywords
protein
sequence
interest
wap
milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92401635A
Other languages
German (de)
French (fr)
Other versions
EP0527063B1 (en
Inventor
Louis-Marie Houdebine
Eve Devinoy
Dominique Thepot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National de la Recherche Agronomique INRA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA filed Critical Institut National de la Recherche Agronomique INRA
Publication of EP0527063A1 publication Critical patent/EP0527063A1/en
Application granted granted Critical
Publication of EP0527063B1 publication Critical patent/EP0527063B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Definitions

  • the present invention relates to a process for preparing a protein of interest in the milk of a transgenic animal. It also relates to the constructions making it possible to obtain these animals, the animals obtained as well as the cells containing the constructions allowing the expression of a heterologous protein.
  • Proteins have thus been produced using genetic recombination techniques, by microorganisms, such as bacteria or yeasts. However, most proteins require, after their synthesis, a maturation stage consisting of chemical modifications of certain reaction groups, glycosylation, etc. Prokaryotic cells do not have the appropriate enzymatic equipment to carry out this maturation, hence the production of inactive proteins and / or with high antigenic power.
  • Another approach therefore consists in having these proteins produced by cells in vivo, via transgenic animals. It is desirable that the system used allows the production of proteins in large quantities, and easily recoverable. It is therefore interesting that the recombinant protein is produced in the mammary gland of transgenic animals, and excreted in milk. It is indeed an easily collectable biological fluid, having a relatively limited complexity and a low proteolytic activity; in addition, the maturation processes of the recombinant proteins will probably be ensured (glycosylation, phosphorylation, cleavage, etc.).
  • the level of proteins thus produced is extremely variable. It is different from one transgenic animal to another, insofar as it is a function of the process of integration of the transgene which is itself variable from one animal to another.
  • the nature of the gene constructs is also essential, the elements regulating the expression of the genes of the milk proteins possibly being multiple and located at various points of the promoter region and of the transcribed part of the gene.
  • the promoters of ovine beta-lactoglobulin, rat WAP and rat casein-beta are able to synthesize these proteins in transgenic mice. The rates are however systematically high only in the case of beta-lactoglobulin.
  • the beta-lactoglobulin promoter directs the synthesis of human alpha 1 -antitrypsin which reaches the value of 7 mg / ml of milk in the milk of a transgenic mouse.
  • the promoter of casein-alpha S1 allows the synthesis of human urokinase, but the promoters of the genes of rat casein beta and rabbit casein beta used to date are of limited activity .
  • the mouse WAP gene promoter directs the synthesis of several foreign proteins (plasminogen activator, CD4) that are secreted in the milk of transgenic mice. The quantities of proteins obtained with this promoter are however relatively modest.
  • the present invention is based on the demonstration of the particular interest of the promoter of the rabbit WAP gene.
  • rabbit WAP whey acidic protein
  • rabbit milk 15 mg / ml of milk
  • the rabbit is potentially a transgenic animal usable on a large scale.
  • the present invention relates to a method in which the sequence controlling the expression of the protein of interest further comprises expression elements located on the fragment between 3 Kb and 6.3 Kb from the end 3 ′ from the WAP promoter.
  • transgenic animals is known and has been widely described with similar constructions in the documents cited above, but also in Günzburg et al., Hennighausen et al., Burdon et al., Reddy et al. as well as in patent WO 90 05188.
  • heterologous protein of interest is meant essentially a protein which is not naturally under the control of the rabbit WAP promoter.
  • the mammalian female used is preferably a rabbit, but these constructions are also effective in other mammals, for example mice.
  • the milk obtained contains the protein of interest which can be isolated or not, then, depending on whether it is in mature or fused form, it can undergo chemical or enzymatic scission if necessary.
  • the DNA constructs used are preferably introduced by microinjection into the fertilized egg at stage one. cell up to 8 cells and then selecting animals meeting the criteria described above, that is to say transgenic and expressing said protein in milk.
  • the promoter region of this WAP gene grafted to the reporter gene for bacterial chloramphenicol acetyl transferase (CAT) contains elements sensitive to the two most important lactogenic hormones, prolactin and glucocorticoids. These hormones intensively stimulate expression of the CAT gene when the hybrid gene is transfected into primary mammary rabbit epithelial cells. The response to hormones depends on the length of the promoter used. The promoter of the rabbit WAP gene is therefore much more effective than the promoters of the mouse and rat WAP genes used to date.
  • the sequence coding for the protein of interest can be preceded towards its 5 ′ end, by a sequence corresponding to the promoter of the complete rabbit WAP gene, or by an equivalent sequence, acting as promoter. It is even possible, in this case, to use the entire WAP gene and a WAP promoter of said gene or of an equivalent sequence.
  • FIG. 5 appended to the present application represents said rabbit WAP gene.
  • equivalent sequence is intended to denote preferably a sequence having at least a length of 3 Kb from the 3 ′ end of the WAP promoter and in particular comprising the expression elements located on the fragment with a length d 'at least 6.3 Kb from the 3 ′ end of the complete rabbit WAP promoter, in particular situated between the HindIII and BamHI sites (FIG. 1).
  • the promoter can comprise a 17 Kb sequence, between the HindIII and EcoRI sites, or a sequence comprising the expression elements located on this fragment.
  • the essential elements of the constructions according to the invention are found on the fragment with a length of 17.6 Kb from the 3 ′ end of the promoter.
  • This long promoter is capable of bringing elements which further favor the expression of the foreign gene which is linked to it, or of making its expression more regularly higher by making it more independent of the site of insertion of the transgene in the genome.
  • the short promoter of 6.3 Kb will give a response to the lactogenic hormones practically identical to that obtained with the long promoter of 17 Kb, and can direct the synthesis of proteins whose genes are associated with it in a vector at very high rates.
  • the invention also relates to constructs as defined above but in which, in the sequence corresponding to the gene for the rabbit WAP protein, the initiator AUG codon is deleted.
  • This modification can be obtained in particular by site-directed mutagenesis.
  • sequence coding for the protein of interest is in fused form with the sequence of all or part of the WAP gene, it is possible to delete the ATG sequence of this protein.
  • the rabbit WAP protein can thus, with this type of construction, be expressed for example in transgenic mice.
  • the gene or cDNA of the protein of interest can be placed in different sites which may lead to levels and different types of constructions, as will emerge from the examples.
  • This process was developed within the framework of the production of heterologous protein by a transgenic animal having integrated in its genome fragments of the gene of the protein WAP, but it can be applied to the purification of any protein which one wishes isolate milk.
  • constructs according to the invention make it possible to obtain completely unexpected results, in particular the 6.3 Kb promoter of WAP associated with the genes of human and bovine growth hormone is capable of directing the synthesis of these proteins in the milk of transgenic mice at very high levels (1-21 mg / ml).
  • the hGH contained in the milk of transgenic mice is structurally intact. HGH has also retained its biological activity (evaluated not by its growth hormone activity but by its prolactin activity). The biological test indicates that the concentration of the hormone is 10 mg / ml, a value in agreement with the values found by the radioimmunological test and by electrophoresis.
  • the promoter of the rabbit WAP gene is therefore much more effective than the promoters of the mouse and rat WAP genes used to date.
  • Table 1 below gives a summary of the results of publications 2 to 15 and therefore highlights the results obtained with the constructions according to the invention, compared with those published in the prior art.
  • the present invention also relates to constructions making it possible to obtain transgenic animals according to the invention.
  • the present invention relates in particular to DNA sequences and vectors allowing the implementation of the method; in particular DNA sequences comprising at least one heterologous gene coding for a protein of interest, under the control of at least one sequence appearing among the expression elements of the rabbit WAP protein and found on the fragment d '' at least 3 Kb in length from the 3 ′ end of the full WAP promoter.
  • the present invention also relates to transgenic animals usable in the process according to the present invention, as well as transformed cells containing the constructs according to the invention.
  • the rabbit is an animal that can potentially be used to obtain abundant recombinant proteins. Up to 100 ml of milk can be collected each day. This milk is very rich in proteins (much richer than the milk of ruminants). It is also easier and less expensive to obtain rabbits than large transgenic animals.
  • the promoter of the rabbit WAP gene also has the best chance of directing the synthesis of recombinant proteins in rabbits.
  • the plasmid p26C is prepared.
  • the p26C plasmid was obtained by introducing the sequence Bam H l-HindIII III of the WAP gene (6.3 Kb fragment of Fig. 1) into the polylinker of the vector p poly III-I (between sites Bam H l and Hind III).
  • the vector p26C is therefore a plasmid capable of receiving a foreign gene placed under the dependence of the WAP promoter 6.3 Kb.
  • the introduction of the foreign gene can take place, for example, in the Sal I site of the poly linker (FIG. 2).
  • the inserts containing the entire promoter and foreign genes can be isolated from the plasmid after a cut at the two Not I sites which are at the ends of the poly linker of the plasmid p-poly III-I.
  • the fragment used to obtain the transgenic mice is between the two NotI sites.
  • a Hind III site was introduced into the leader sequence of the gene (leader) by site-directed mutagenesis to serve as a cloning site.
  • Plasmid pJ4 obtained from plasmid p26 (according to FIG. 3), contains the promoter of the rabbit WAP gene (6.3 Kb) and the bovine growth hormone (bGH) gene. The fragment used to obtain the transgenic mice is between the two NotI sites.
  • the pW3 and pJ4 fragments were used to obtain transgenic animals.
  • the transgenic mice were obtained by the conventional microinjection technique (Brinster et al., Proc. Natl. Acad. Sci. USA (1985) 82 , 4438-4442). 1-2- ⁇ l containing 500 copies of the gene were injected into the male pronucleus of mouse embryos. The constructions were carried out in the vector p-poly III-I (Lathe et al., Gene (1987) 57 , 193-201). The Not l - Not l fragments of this vector containing the recombinant genes were microinjected. The embryos were then transferred to the oviduct of hormonally prepared adoptive females.
  • the biological activity of hGH was evaluated by adding milk to the culture medium of rabbit breast cells or explants.
  • the hGH contained in milk induced the expression of the casein- ⁇ gene evaluated by measuring the mRNA and the protein.
  • EXAMPLE 4 PRODUCTION OF HUMAN OR BOVINE GROWTH HORMONE IN TRANSGENIC MOUSE MILK HAVING THE CONSTRUCTIONS pW3 AND pJ4
  • the hormone concentrations were determined by specific radioimmunological tests.
  • the identification of hGH in the milk of a transgenic mouse is carried out as follows.
  • the mouse milk is centrifuged at 150,000 g for one hour to sediment the casein micelles.
  • the supernatant (1 ⁇ l per well) was collected and examined by polyacrylamide gel electrophoresis, in the presence of control human growth hormone and a control milk. The results are reported in Figure 4.
  • Animals which have integrated the pW3 construct give hGH concentrations of the order of 10 mg / ml of milk and can reach 21 mg / ml.
  • the animals having integrated the pJ4 construct produce about 5 mg / ml of bGH milk and up to 17 mg / ml.
  • the method according to the present invention makes it possible to collect 1.5 ml of milk / mammary gland of mice (by putting the mammary gland in ice). 200 lactating mice expressing a foreign protein at a concentration of 3 - 5 mg / ml therefore provide 1 g of the crude protein.
  • the gene constructs used to express recombinant proteins in the milk of transgenic animals contain in all cases the regulatory region of the rabbit WAP gene: BamHI-HindIII fragment (6.3 Kb) or EcoRI-HindIII fragment (17.6 Kb).
  • the plasmids WAP-hGH, WAP bGH, WAP ⁇ -AT, and WAP-EPO respectively contain the whole genes (leader sequence, exons, introns and transcription terminator) of the human growth hormone (hGH), of the hormone of bovine growth (bGH), human ⁇ l -antitrypsin mutated to Arg358 and human erythropoeitin.
  • the genes were associated with the regulatory region of the WAP gene at the HindIII site.
  • the WAP-FVIII- ⁇ II construct contains the human factor VIII cDNA in its ⁇ II form preceded by an intron of the human factor VIII gene. This intron-cDNA set was introduced into the HindIII site of the entire rabbit WAP gene (FIG. 6).
  • EXAMPLE 6 IDENTIFICATION OF THE ACTIVITY OF THE REGULATORY REGION OF THE WAP GENE OF RABBIT IN VITRO
  • the sensitivity of the gene to hormones is exactly the same as that of the endogenous WAP gene in cells.
  • the -3000-1806 bp and -6300-3000 bp regions therefore contain essential regulatory elements for the WAP gene to be expressed in an intense manner (FIG. 8).
  • the 17600-6300 bp fragment does not provide additional stimulation in vitro, which does not exclude that it can have such an action in vitro in transgenic animals.
  • FIGURE 6
  • FIGURE 7
  • Diagram of the various constructions comprising the CAT gene placed under the dependence of variable lengths of the rabbit WAP gene.
  • FIGURE 8

Abstract

The present invention relates to a process for the preparation of a heterologous protein of interest in the mature form or in the fused form from the milk of mammalian female, a process in which: - the said female is bred and, - the milk is recovered from which the said protein is recovered and separated if necessary, characterised in that the said female is a transgenic animal into whose genome a sequence encoding the said protein of interest has been integrated under the control of at least one sequence which is among the elements for the expression of rabbit WAP protein and which is present in the fragment which is at least 3 Kb in length from the 3% end of the complete WAP promoter. It also relates to the milk product obtained and to an eukaryotic cell which has integrated the sequences described.

Description

La présente invention concerne un procédé de préparation d'une protéine d'intérêt dans le lait d'un animal transgénique. Elle concerne également les constructions permettant d'obtenir ces animaux, les animaux obtenus ainsi que les cellules contenant les constructions permettant l'expression d'une protéine hétérologue.The present invention relates to a process for preparing a protein of interest in the milk of a transgenic animal. It also relates to the constructions making it possible to obtain these animals, the animals obtained as well as the cells containing the constructions allowing the expression of a heterologous protein.

Plusieurs voies ont été poursuivies pour obtenir des protéines présentant un intérêt biologique, thérapeutique, ou industriel, et produites naturellement en petites quantités ou sous une forme difficile à purifier.Several routes have been pursued to obtain proteins of biological, therapeutic or industrial interest, and produced naturally in small quantities or in a form which is difficult to purify.

Des protéines ont ainsi pu être produites grâce à des techniques de recombinaison génétique, par des microorganismes, comme des bactéries ou des levures. Cependant, la plupart des protéines requièrent, après leur synthèse, un stade de maturation consistant en modifications chimiques de certains groupements réactionnels, glycosylation, etc. Les cellules procaryotes ne disposent pas de l'équipement enzymatique adéquat pour effectuer cette maturation, d'où l'obtention de protéines inactives et/ou à fort pouvoir antigénique.Proteins have thus been produced using genetic recombination techniques, by microorganisms, such as bacteria or yeasts. However, most proteins require, after their synthesis, a maturation stage consisting of chemical modifications of certain reaction groups, glycosylation, etc. Prokaryotic cells do not have the appropriate enzymatic equipment to carry out this maturation, hence the production of inactive proteins and / or with high antigenic power.

Il est donc préférable de synthétiser ces protéines dans des cellules eucaryotes, qui réaliseront les transformations enzymatiques appropriées. Cependant, la culture à grande échelle de cellules tissulaires pose un certain nombre de difficultés techniques et économiques.It is therefore preferable to synthesize these proteins in eukaryotic cells, which will carry out the appropriate enzymatic transformations. However, large-scale cultivation of tissue cells poses a number of technical and economic difficulties.

Une autre approche consiste donc à faire produire ces protéines par des cellules in vivo, par l'intermédiaire d'animaux transgéniques. Il est souhaitable que le système utilisé permette la production de protéines en grande quantité, et facilement récupérable. Il est donc intéressant que la protéine recombinante soit produite au niveau de la glande mammaire d'animaux transgéniques, et excrétée dans le lait. Il s'agit en effet d'un fluide biologique aisément collectable, ayant une complexité relativement limitée et une faible activité protéolytique ; en outre, les processus de maturation des protéines recombinantes seront probablement assurés (glycosylation, phosphorylation, clivage, etc.).Another approach therefore consists in having these proteins produced by cells in vivo, via transgenic animals. It is desirable that the system used allows the production of proteins in large quantities, and easily recoverable. It is therefore interesting that the recombinant protein is produced in the mammary gland of transgenic animals, and excreted in milk. It is indeed an easily collectable biological fluid, having a relatively limited complexity and a low proteolytic activity; in addition, the maturation processes of the recombinant proteins will probably be ensured (glycosylation, phosphorylation, cleavage, etc.).

On a ainsi réussi à faire synthétiser par la glande mammaire de souris ou de brebis des protéines du lait d'une autre espèce ou des protéines normalement absentes du lait (Réf. 1 à 15).We have thus succeeded in making the mammary gland of mice or sheep synthesize milk proteins of another species or proteins normally absent from milk (Ref. 1 to 15).

Toutefois, le taux de protéines ainsi produites est extrêmement variable. Il est différent d'un animal transgénique à l'autre, dans la mesure où il est fonction du processus d'intégration du transgène qui est lui-même variable d'un animal à l'autre. La nature des constructions de gène est également essentielle, les éléments régulant l'expression des gènes des protéines du lait pouvant être multiples et situés en divers points de la région promotrice et de la partie transcrite du gène. Ainsi, les promoteurs de la béta-lactoglobuline ovine, de la WAP de rat et de la caséine-béta de rat sont capables de faire synthétiser ces protéines chez des souris transgéniques. Les taux ne sont toutefois systématiquement élevés que dans le cas de la béta-lactoglobuline. De même, le promoteur de la béta-lactoglobuline dirige la synthése de l'alphal-antitrypsine humaine qui atteint la valeur de 7 mg/ml de lait dans le lait d'une souris transgénique. Le promoteur de la caséine-alphaSl permet la synthèse de l'urokinase humaine, mais les promoteurs des gènes de la caséine-béta de rat et de la caséine-béta de lapin utilisés jusqu'à ce jour, sont d'une activité limitée. Le promoteur du gène de la WAP de souris dirige la synthèse de plusieurs protéines étrangères (activateur de plasminogène, CD4) qui sont sécrétées dans le lait de souris transgéniques. Les quantités de protéines obtenues avec ce promoteur sont toutefois relativement modestes.However, the level of proteins thus produced is extremely variable. It is different from one transgenic animal to another, insofar as it is a function of the process of integration of the transgene which is itself variable from one animal to another. The nature of the gene constructs is also essential, the elements regulating the expression of the genes of the milk proteins possibly being multiple and located at various points of the promoter region and of the transcribed part of the gene. Thus, the promoters of ovine beta-lactoglobulin, rat WAP and rat casein-beta are able to synthesize these proteins in transgenic mice. The rates are however systematically high only in the case of beta-lactoglobulin. Likewise, the beta-lactoglobulin promoter directs the synthesis of human alpha 1 -antitrypsin which reaches the value of 7 mg / ml of milk in the milk of a transgenic mouse. The promoter of casein-alpha S1 allows the synthesis of human urokinase, but the promoters of the genes of rat casein beta and rabbit casein beta used to date are of limited activity . The mouse WAP gene promoter directs the synthesis of several foreign proteins (plasminogen activator, CD4) that are secreted in the milk of transgenic mice. The quantities of proteins obtained with this promoter are however relatively modest.

De plus, il arrive que la spécificité du promoteur soit modifiée par son association à un gène étranger. C'est ainsi que Günzburg et al . (Molecular Endocrinology 1991) obtiennent la secrétion d'hormone de croissance à l'aide d'un ADN recombinant sous la dépendance du promoteur de la WAP de souris, chez des animaux transgéniques ; mais l'hormone de croissance est alors également produite dans le cervelet, dans les cellules gliales de Bergman. De tels phénomènes peuvent résulter dans une toxicité et dans la mort prématurée de l'animal.In addition, it can happen that the specificity of the promoter is modified by its association with a foreign gene. This is how Günzburg et al. (Molecular Endocrinology 1991) obtain growth hormone secretion using recombinant DNA under the control of the mouse WAP promoter, in transgenic animals; but growth hormone is then also produced in the cerebellum, in Bergman's glial cells. Such phenomena can result in toxicity and in the premature death of the animal.

La présente invention repose sur la mise en évidence de l'intérêt particulier du promoteur du gène de la WAP de lapin. En effet, la WAP de lapin ("whey acidic protein") est une protéine relativement abondante du lait de lapin (15 mg/ml de lait), et le lapin est potentiellement un animal transgénique utilisable à grande échelle.The present invention is based on the demonstration of the particular interest of the promoter of the rabbit WAP gene. Indeed, rabbit WAP ("whey acidic protein") is a relatively abundant protein in rabbit milk (15 mg / ml of milk), and the rabbit is potentially a transgenic animal usable on a large scale.

La présente invention concerne un procédé de préparation d'une protéine hétérologue d'intérêt sous forme mature ou sous forme fusionnée dans le lait d'une femelle de mammifère, procédé dans lequel :

  • on élève ladite femelle et,
  • on récupère le lait d'où l'on récupère ladite protéine que l'on sépare si nécessaire,

caractérisé en ce que ladite femelle est un animal transgénique dans le génome duquel a été intégrée une séquence codant pour ladite protéine d'intérêt sous le contrôle d'au moins une séquence figurant parmi les éléments d'expression de la protéine WAP de lapin et se trouvant sur le fragment d'une longueur d'au moins 3 Kb à partir de l'extrémité 3′ du promoteur WAP complet.The present invention relates to a process for preparing a heterologous protein of interest in mature form or in fused form in the milk of a mammalian female, process in which:
  • we raise said female and,
  • the milk is recovered from which the said protein is recovered which is separated if necessary,

characterized in that said female is a transgenic animal into the genome of which a sequence coding for said protein of interest has been integrated under the control of at least one sequence appearing among the expression elements of the rabbit WAP protein and is found on the fragment at least 3 Kb in length from the 3 ′ end of the full WAP promoter.

De préférence, la présente invention concerne un procédé dans lequel la séquence contrôlant l'expression de la protéine d'intérêt comprend en outre des éléments d'expression situés sur le fragment compris entre 3 Kb et 6,3 Kb à partir de l'extrémité 3′ du promoteur WAP.Preferably, the present invention relates to a method in which the sequence controlling the expression of the protein of interest further comprises expression elements located on the fragment between 3 Kb and 6.3 Kb from the end 3 ′ from the WAP promoter.

L'obtention d'animaux transgéniques est connue et a été largement décrite avec des constructions voisines dans les documents cités précédemment mais également dans Günzburg et al., Hennighausen et al., Burdon et al., Reddy et al. ainsi que dans le brevet WO 90 05188.Obtaining transgenic animals is known and has been widely described with similar constructions in the documents cited above, but also in Günzburg et al., Hennighausen et al., Burdon et al., Reddy et al. as well as in patent WO 90 05188.

La description détaillée des méthodes de transgénèse ne sera pas rappelée en détail, les documents ci-dessus sont incorporés dans la présente description par référence expresse.The detailed description of the transgenesis methods will not be recalled in detail, the above documents are incorporated into this description by express reference.

Par "protéine hétérologue d'intérêt", on entend désigner essentiellement une protéine qui n'est pas naturellement sous le contrôle du promoteur WAP de lapin.By "heterologous protein of interest" is meant essentially a protein which is not naturally under the control of the rabbit WAP promoter.

Dans le procédé selon l'invention, la femelle de mammifère utilisée est de préférence une lapine mais ces constructions sont efficaces également dans d'autres mammifères, par exemple les souris.In the method according to the invention, the mammalian female used is preferably a rabbit, but these constructions are also effective in other mammals, for example mice.

Le lait obtenu contient la protéine d'intérêt qui peut être isolée ou non puis, suivant qu'elle est sous forme mature ou fusionnée, elle peut subir une scission chimique ou enzymatique si nécessaire.The milk obtained contains the protein of interest which can be isolated or not, then, depending on whether it is in mature or fused form, it can undergo chemical or enzymatic scission if necessary.

Les constructions d'ADN utilisées sont de préférence introduites par microinjection au niveau de l'oeuf fécondé au stade une cellule jusqu'à 8 cellules puis on sélectionne les animaux répondant aux critères décrits précédemment, c'est-à-dire transgéniques et exprimant ladite protéine dans le lait.The DNA constructs used are preferably introduced by microinjection into the fertilized egg at stage one. cell up to 8 cells and then selecting animals meeting the criteria described above, that is to say transgenic and expressing said protein in milk.

La région promotrice de ce gène WAP greffée au gène rapporteur de la chloramphénicol acétyl transférase (CAT) bactérienne contient les éléments sensibles aux deux hormones lactogènes les plus importantes, la prolactine et les glucocorticoïdes. Ces hormones stimulent de manière intense l'expression du gène CAT lorsque le gène hybride est transfecté dans des cellules épithéliales primaires mammaires de lapine. La réponse aux hormones dépend de la longueur du promoteur utilisé. Le promoteur du gène de la WAP de lapin est donc beaucoup plus efficace que les promoteurs des gènes de la WAP de souris et de rat, utilisés jusqu'à ce jour.The promoter region of this WAP gene grafted to the reporter gene for bacterial chloramphenicol acetyl transferase (CAT) contains elements sensitive to the two most important lactogenic hormones, prolactin and glucocorticoids. These hormones intensively stimulate expression of the CAT gene when the hybrid gene is transfected into primary mammary rabbit epithelial cells. The response to hormones depends on the length of the promoter used. The promoter of the rabbit WAP gene is therefore much more effective than the promoters of the mouse and rat WAP genes used to date.

En particulier, dans le procédé selon la présente invention, la séquence codant pour la protéine d'intérêt peut être précédée vers son extrémité 5′, d'une séquence correspondant au promoteur du gène WAP de lapin complet, ou d'une séquence équivalente, assurant la fonction de promoteur. Il est même possible, dans ce cas, d'utiliser la totalité du gène WAP et un promoteur WAP dudit gène ou d'une séquence équivalente. La figure 5 annexée à la présente demande représente ledit gène WAP de lapin.In particular, in the method according to the present invention, the sequence coding for the protein of interest can be preceded towards its 5 ′ end, by a sequence corresponding to the promoter of the complete rabbit WAP gene, or by an equivalent sequence, acting as promoter. It is even possible, in this case, to use the entire WAP gene and a WAP promoter of said gene or of an equivalent sequence. FIG. 5 appended to the present application represents said rabbit WAP gene.

Par "séquence équivalente", on entend désigner de préférence une séquence ayant au moins une longueur de 3 Kb à partir de l'extrémité 3′ du promoteur WAP et en particulier comportant les éléments d'expression situés sur le fragment d'une longueur d'au moins 6,3 Kb à partir de l'extrémité 3′ du promoteur WAP de lapin complet, notamment située entre les sites HindIII et BamHI (figure 1).The term “equivalent sequence” is intended to denote preferably a sequence having at least a length of 3 Kb from the 3 ′ end of the WAP promoter and in particular comprising the expression elements located on the fragment with a length d 'at least 6.3 Kb from the 3 ′ end of the complete rabbit WAP promoter, in particular situated between the HindIII and BamHI sites (FIG. 1).

Le promoteur peut comporter une séquence de 17 Kb, comprise entre les sites HindIII et EcoRI, ou une séquence comportant les éléments d'expression situés sur ce fragment. Les éléments essentiels des constructions selon l'invention se trouvent sur le fragment d'une longueur de 17,6 Kb à partir de l'extrémité 3′ du promoteur.The promoter can comprise a 17 Kb sequence, between the HindIII and EcoRI sites, or a sequence comprising the expression elements located on this fragment. The essential elements of the constructions according to the invention are found on the fragment with a length of 17.6 Kb from the 3 ′ end of the promoter.

Ce long promoteur est susceptible d'apporter des éléments qui favorisent encore l'expression du gène étranger qui lui est lié, ou de rendre son expression plus régulièrement élevée en la rendant plus indépendante du site d'insertion du transgène dans le génome.This long promoter is capable of bringing elements which further favor the expression of the foreign gene which is linked to it, or of making its expression more regularly higher by making it more independent of the site of insertion of the transgene in the genome.

Le promoteur court de 6,3 Kb donnera une réponse aux hormones lactogènes pratiquement identique à celle obtenue avec le promoteur long de 17 Kb, et peut diriger la synthèse de protéines dont les gènes lui sont associés dans un vecteur à des taux très élevés.The short promoter of 6.3 Kb will give a response to the lactogenic hormones practically identical to that obtained with the long promoter of 17 Kb, and can direct the synthesis of proteins whose genes are associated with it in a vector at very high rates.

L'invention concerne également des constructions telles que définies ci-dessus mais dans lesquelles, dans la séquence correspondant au gène de la protéine WAP de lapin, le codon AUG initiateur est délété.The invention also relates to constructs as defined above but in which, in the sequence corresponding to the gene for the rabbit WAP protein, the initiator AUG codon is deleted.

Cette modification peut être obtenue notamment par mutagénèse dirigée.This modification can be obtained in particular by site-directed mutagenesis.

Lorsque la séquence codant pour la protéine d'intérêt est sous forme fusionnée avec la séquence de tout ou partie du gène WAP, il est possible de supprimer la séquence ATG de cette protéine.When the sequence coding for the protein of interest is in fused form with the sequence of all or part of the WAP gene, it is possible to delete the ATG sequence of this protein.

La protéine WAP de lapin pourra ainsi, avec ce type de construction, être exprimée par exemple chez des souris transgéniques.The rabbit WAP protein can thus, with this type of construction, be expressed for example in transgenic mice.

Dans ce type de construction comprenant le gène de la protéine WAP de lapin, ayant éventuellement perdu le codon AUG initiateur, le gène ou l'ADNc de la protéine d'intérêt peut être placé en différents sites qui pourront conduire à des niveaux et des types de constructions différents, comme cela ressortira des exemples.In this type of construct comprising the gene of the rabbit WAP protein, optionally having lost the AUG initiator codon, the gene or cDNA of the protein of interest can be placed in different sites which may lead to levels and different types of constructions, as will emerge from the examples.

Selon un autre de ses aspects, la présente invention fournit un procédé pour récupérer le lait produit par une femelle de mammifère et la protéine qu'il contient, caractérisé en ce que, pour récupérer la protéine d'intérêt dans le lait de ladite femelle de mammifère,

  • a) on recueille les glandes mammaires,
  • b) on laisse incuber les glandes mammaires à une température d'environ 0°C pendant une durée variant de deux heures à 18 heures,
  • c) on récupère le lait ayant spontanément exsudé des glandes,
  • d) on isole la protéine d'intérêt à partir du lait et on obtient ladite protéine purifiée.
According to another of its aspects, the present invention provides a method for recovering the milk produced by a mammalian female and the protein which it contains, characterized in that, for recovering the protein of interest in the milk of said female of mammal,
  • a) the mammary glands are collected,
  • b) the mammary glands are incubated at a temperature of approximately 0 ° C. for a period varying from two hours to 18 hours,
  • c) the milk having spontaneously exuded from the glands is recovered,
  • d) the protein of interest is isolated from milk and said purified protein is obtained.

Ce procédé a été mis au point dans le cadre de la production de protéine hétérologue par un animal transgénique ayant intégré dans son génôme des fragments du gène de la protéine WAP, mais il peut être appliqué à la purification de toute protéine que l'on désire isoler du lait.This process was developed within the framework of the production of heterologous protein by a transgenic animal having integrated in its genome fragments of the gene of the protein WAP, but it can be applied to the purification of any protein which one wishes isolate milk.

Il représente un avantage considérable par rapport aux procédés classiques de traite des mammifères non-ruminants, sur le plan des quantités obtenues, surtout pour des petits animaux comme la souris (24). La composition du lait recueilli est identique à celle du lait produit naturellement. Ce procédé permet en outre un transfert plus aisé des produits obtenus du lieu de production au lieu de purification et de traitement, par transport des glandes mammaires dans de la glace.It represents a considerable advantage over conventional methods for milking non-ruminant mammals, in terms of the quantities obtained, especially for small animals such as mice (24). The composition of the milk collected is identical to that of naturally produced milk. This process also allows easier transfer of the products obtained from the place of production to the place of purification and treatment, by transporting the mammary glands in ice.

Le procédé de préparation de protéine hétérologue de la présente invention, selon l'une quelconque de ses variantes, permet d'obtenir un grand nombre de protéines. Parmi ces protéines, il faut citer :

  • les facteurs de croissance,
  • les interleukines,
  • les facteurs de stimulation,
  • les kinases,
  • les facteurs de coagulation,
  • l'alpha-antitrypsine,
  • l'hirudine.

et en particulier :
  • l'érythropoïétine,
  • le G-CSF,
  • l'alpha-antitrypsine,
  • l'urokinase,
  • le facteur VIII.
The method for preparing heterologous protein of the present invention, according to any one of its variants, makes it possible to obtain a large number of proteins. Among these proteins, we should mention:
  • growth factors,
  • the interleukins,
  • stimulating factors,
  • kinases,
  • coagulation factors,
  • alpha-antitrypsin,
  • hirudin.

and especially :
  • erythropoietin,
  • the G-CSF,
  • alpha-antitrypsin,
  • urokinase,
  • factor VIII.

On peut citer les constructions suivantes :

  • construction WAP-alphal-antitrypsine humaine (analogue Arg 358) : le gène entier alphal-antitrypsine humaine ayant l'Arg 358 à la place de la Meth 358 (Courtney, Bull. Inst. Pasteur (1988) 86, 85-94) a été fusionné au promoteur long (17,6 Kb) du gène de la WAP de lapin au site Hind III de la séquence 5′P non traduite, sur le modèle des constructions WAP-GH. Plusieurs lignées de souris expriment le gène humain à la concentration de 2 et 5 mg/ml de lait.
  • construction WAP-érythropoïétine humaine : le gène entier de l'érythropoïétine humaine (Semenza et al., Proc. Natl. Acad. Sci. USA (1989) 86, 2301-2305) est fusionné au promoteur (6,3 Kb et 17,6 Kb) du gène de la WAP de lapin.
  • construction WAP-facteur VIII-deltaII humain : l'ADNc du facteur VIII-deltaII humain (délété de la région B [Meulien et al., Prot. Engin (1988) 2, 301-306]) précédé du premier intron du gène du facteur VIII et dépourvu de sa séquence de polyadénylation, a été introduit à l'intérieur du gène WAP de lapin entier au site Hind III introduit par mutagénèse dirigée et qui précède l'AUG naturel.
We can cite the following constructions:
  • WAP-alpha l -antitrypsin construct (Arg 358 analog): the entire alpha l -antitrypsin gene having Arg 358 in place of Meth 358 (Courtney, Bull. Inst. Pasteur (1988) 86 , 85-94 ) was fused to the long promoter (17.6 Kb) of the WAP gene of rabbit at the Hind III site of the untranslated 5′P sequence, on the model of the WAP-GH constructs. Several mouse lines express the human gene at the concentration of 2 and 5 mg / ml of milk.
  • WAP-human erythropoietin construct: the entire gene for human erythropoietin (Semenza et al., Proc. Natl. Acad. Sci. USA (1989) 86 , 2301-2305) is fused to the promoter (6.3 Kb and 17, 6 Kb) of the rabbit WAP gene.
  • construction WAP-factor VIII-deltaII human: the cDNA of factor VIII-deltaII human (deleted from region B [Meulien et al., Prot. Engin (1988) 2 , 301-306]) preceded by the first intron of the gene factor VIII and lacking its polyadenylation sequence, was introduced into the entire rabbit WAP gene at the Hind III site introduced by site-directed mutagenesis and which precedes the natural AUG.

Les constructions selon l'invention permettent d'obtenir des résultats tout à fait inattendus, notamment le promoteur de 6,3 Kb de la WAP associé aux gènes de l'hormone de croissance humaine et bovine est capable de diriger la synthèse de ces protéines dans le lait de souris transgéniques à des taux très élevés (1-21 mg/ml).The constructs according to the invention make it possible to obtain completely unexpected results, in particular the 6.3 Kb promoter of WAP associated with the genes of human and bovine growth hormone is capable of directing the synthesis of these proteins in the milk of transgenic mice at very high levels (1-21 mg / ml).

L'hGH contenue dans le lait des souris transgéniques est structuralement intacte. L'hGH a également conservé son activité biologique (évaluée non par son activité hormone de croissance mais par son activité prolactine). Le test biologique indique que la concentration de l'hormone est de 10 mg/ml, une valeur en accord avec les valeurs trouvées par le test radioimmunologique et par l'électrophorèse.The hGH contained in the milk of transgenic mice is structurally intact. HGH has also retained its biological activity (evaluated not by its growth hormone activity but by its prolactin activity). The biological test indicates that the concentration of the hormone is 10 mg / ml, a value in agreement with the values found by the radioimmunological test and by electrophoresis.

Le promoteur du gène de la WAP de lapin est donc beaucoup plus efficace que les promoteurs des gènes de la WAP de souris et de rat, utilisés jusqu'à ce jour.The promoter of the rabbit WAP gene is therefore much more effective than the promoters of the mouse and rat WAP genes used to date.

Le tableau 1 suivant donne un résumé des résultats des publications 2 à 15 et met donc en valeur les résultats obtenus avec les constructions selon l'invention, par rapport à ceux publiés dans l'art antérieur.

Figure imgb0001
Table 1 below gives a summary of the results of publications 2 to 15 and therefore highlights the results obtained with the constructions according to the invention, compared with those published in the prior art.
Figure imgb0001

Une des raisons essentielles peut tenir dans le fait que le fragment d'ADN de lapin (6,3 Kb) était beaucoup plus long que son homologue de souris et de rat (2,6 Kb et 0,9 Kb). Des éléments régulateurs essentiels peuvent manquer dans les fragments d'ADN de souris et de rat utilisés.One of the main reasons may be that the rabbit DNA fragment (6.3 Kb) was much longer than its mouse and rat counterpart (2.6 Kb and 0.9 Kb). Essential regulatory elements may be missing in the mouse and rat DNA fragments used.

La présente invention concerne également des constructions permettant d'obtenir des animaux transgéniques selon l'invention.The present invention also relates to constructions making it possible to obtain transgenic animals according to the invention.

La présente invention concerne notamment les séquences d'ADN et les vecteurs permettant la mise en oeuvre du procédé ; en particulier les séquences d'ADN comportant au moins un gène hétérologue codant pour une protéine d'intérêt, sous le contrôle d'au moins une séquence figurant parmi les éléments d'expression de la protéine WAP de lapin et se trouvant sur le fragment d'une longueur d'au moins 3 Kb à partir de l'extrémité 3′ du promoteur WAP complet.The present invention relates in particular to DNA sequences and vectors allowing the implementation of the method; in particular DNA sequences comprising at least one heterologous gene coding for a protein of interest, under the control of at least one sequence appearing among the expression elements of the rabbit WAP protein and found on the fragment d '' at least 3 Kb in length from the 3 ′ end of the full WAP promoter.

La présente invention concerne également des animaux transgéniques utilisables dans le procédé selon la présente invention, ainsi que des cellules transformées contenant les constructions selon l'invention.The present invention also relates to transgenic animals usable in the process according to the present invention, as well as transformed cells containing the constructs according to the invention.

Bien que les animaux en cause puissent être très divers, le lapin est un animal potentiellement utilisable pour obtenir des protéines recombinantes en abondance. Jusqu'à 100 ml de lait peuvent être collectés chaque jour. Ce lait est très riche en protéines (beaucoup plus riche que le lait des ruminants). Il est par ailleurs plus facile et moins onéreux d'obtenir des lapins que des gros animaux transgéniques. Le promoteur du gène de la WAP de lapin a, de plus, toutes les chances de diriger au mieux la synthèse de protéines recombinantes chez le lapin.Although the animals involved can be very diverse, the rabbit is an animal that can potentially be used to obtain abundant recombinant proteins. Up to 100 ml of milk can be collected each day. This milk is very rich in proteins (much richer than the milk of ruminants). It is also easier and less expensive to obtain rabbits than large transgenic animals. The promoter of the rabbit WAP gene also has the best chance of directing the synthesis of recombinant proteins in rabbits.

D'autres caractéristiques et avantages de la présente invention invention apparaîtront à la lecture des exemples ci-après dans lesquels on se réfèrera aux figures suivantes :

  • FIGURE 1 : cartographie du gène de la WAP de lapin.
  • FIGURE 2a: schéma de la construction du plasmide pW₃.
  • FIGURE 2b: polylinker du plasmide p-polyIII-I
  • FIGURE 3 : schéma de la construction du plasmide pJ₄.
  • FIGURE 4 : production d'hormone de croissance humaine et bovine dans des lignées de souris transgéniques abritant les constructions pW₃ et pJ₄.
  • FIGURE 5 : séquence du gène WAP de lapin.
  • FIGURE 6 : schémas des différentes constructions utilisées in vivo.
  • FIGURE 7 : schémas des constructions contenant le gène rapporteur CAT et des longueurs variables du promoteur WAP.
  • FIGURE 8 : efficacité des constructions décrites dans la figure 7.
Other characteristics and advantages of the present invention will appear on reading the examples below in which reference will be made to the following figures:
  • FIGURE 1: mapping of the rabbit WAP gene.
  • FIGURE 2a: diagram of the construction of the plasmid pW₃.
  • FIGURE 2b: polylinker of the plasmid p-polyIII-I
  • FIGURE 3: diagram of the construction of the plasmid pJ₄.
  • FIGURE 4: production of human and bovine growth hormone in lines of transgenic mice harboring the constructions pW₃ and pJ₄.
  • FIGURE 5: Rabbit WAP gene sequence.
  • FIGURE 6: diagrams of the different constructions used in vivo.
  • FIGURE 7: diagrams of the constructions containing the CAT reporter gene and variable lengths of the WAP promoter.
  • FIGURE 8: efficiency of the constructions described in figure 7.

EXEMPLE 1EXAMPLE 1 :: CONSTRUCTION DU PLASMIDE pW3CONSTRUCTION OF THE PLASMID pW3

On prépare tout d'abord le plasmide p26C.First of all, the plasmid p26C is prepared.

Le plasmide p26C a été obtenu en introduisant la séquence Bam Hl-Hind III du gène WAP (fragment 6,3 Kb de la Fig. 1) dans le poly linker du vecteur p-poly III-I (entre les sites Bam Hl et Hind III).The p26C plasmid was obtained by introducing the sequence Bam H l-HindIII III of the WAP gene (6.3 Kb fragment of Fig. 1) into the polylinker of the vector p poly III-I (between sites Bam H l and Hind III).

Au cours de ce clonage, le site Bam Hl a été supprimé et remplacé par le site Cla I qui figure dans le vecteur p26C (Fig.2). Le vecteur p26C est donc un plasmide capable de recevoir un gène étranger placé sous la dépendance du promoteur WAP 6,3 Kb. L'introduction du gène étranger peut se faire par exemple dans le site Sal I du poly linker (Fig.2). Les inserts contenant la totalité du promoteur et des gènes étrangers peuvent être isolés du plasmide après une coupure aux deux sites Not l qui sont aux extrémités du poly linker du plasmide p-poly III-I.During this cloning, the Bam H l has been deleted and replaced by the Cla I site contained in the vector p26C (Fig.2). The vector p26C is therefore a plasmid capable of receiving a foreign gene placed under the dependence of the WAP promoter 6.3 Kb. The introduction of the foreign gene can take place, for example, in the Sal I site of the poly linker (FIG. 2). The inserts containing the entire promoter and foreign genes can be isolated from the plasmid after a cut at the two Not I sites which are at the ends of the poly linker of the plasmid p-poly III-I.

Le plasmide pW₃, obtenu à partir du plasmide p26C (selon la figure 2), contient le promoteur du gène de la WAP de lapin (6,3 Kb) et le gène de l'hormone de croissance humaine (hGH). Le fragment utilisé pour obtenir les souris transgéniques est compris entre les deux sites Notl.The plasmid pW₃, obtained from the plasmid p26C (according to FIG. 2), contains the promoter of the rabbit WAP gene (6.3 Kb) and the gene of human growth hormone (hGH). The fragment used to obtain the transgenic mice is between the two NotI sites.

Un site Hind III a été introduit dans la séquence de tête du gène (leader) par mutagénèse dirigée pour servir de site de clonage.A Hind III site was introduced into the leader sequence of the gene (leader) by site-directed mutagenesis to serve as a cloning site.

EXEMPLE 2: EXAMPLE 2 : CONSTRUCTION DU PLASMIDE pJ4CONSTRUCTION OF PLASMID pJ4

Le plasmide pJ₄, obtenu à partir du plasmide p26 (selon la figure 3), contient le promoteur du gène de la WAP de lapin (6,3 Kb) et le gène de l'hormone de croissance bovine (bGH). Le fragment utilisé pour obtenir les souris transgéniques est compris entre les deux sites Notl.Plasmid pJ₄, obtained from plasmid p26 (according to FIG. 3), contains the promoter of the rabbit WAP gene (6.3 Kb) and the bovine growth hormone (bGH) gene. The fragment used to obtain the transgenic mice is between the two NotI sites.

La souche d'E. Coli contenant le plasmide p26 a été déposée le 12 juin 1991, sous le n° I-1116 à la collection nationale de culture de microorganismes de l'Institut Pasteur, 25 rue du Docteur Roux, 75724 PARIS CEDEX 15.The strain of E. Coli containing the plasmid p26 was deposited on June 12, 1991, under the n ° I-1116 at the national collection of culture of microorganisms of the Pasteur Institute, 25 rue du Docteur Roux, 75724 PARIS CEDEX 15.

EXEMPLE 3EXAMPLE 3 :: OBTENTION DE SOURIS TRANSGENIQUESOBTAINING TRANSGENIC MICE

Les fragments pW₃ et pJ₄ ont été utilisés pour obtenir des animaux transgéniques. Les souris transgéniques ont été obtenues par la technique classique de microinjection (Brinster et al., Proc. Natl. Acad. Sci. USA (1985) 82, 4438-4442). 1-2-pl contenant 500 copies du gène ont été injectés dans le pronucleus mâle d'embryons de souris. Les constructions ont été réalisées dans le vecteur p-poly III-I (Lathe et al., Gene (1987) 57, 193-201). Les fragments Not l - Not l de ce vecteur contenant les gènes recombinés ont été microinjectés. Les embryons ont ensuite été transférés dans l'oviducte de femelles adoptives hormonalement préparées. Environ 10% des embryons manipulés ont donné naissance à des souriceaux et 2-5 % des embryons manipulés à des souriceaux transgéniques. La présence des transgènes a été révélée par la technique de transfert de Southern à partir de l'ADN extrait des queues des souris. Les concentrations de l'hormone de croissance dans le sang et dans le lait des animaux ont été évaluées à l'aide de tests radioimmunologiques spécifiques.The pW₃ and pJ₄ fragments were used to obtain transgenic animals. The transgenic mice were obtained by the conventional microinjection technique (Brinster et al., Proc. Natl. Acad. Sci. USA (1985) 82 , 4438-4442). 1-2-µl containing 500 copies of the gene were injected into the male pronucleus of mouse embryos. The constructions were carried out in the vector p-poly III-I (Lathe et al., Gene (1987) 57 , 193-201). The Not l - Not l fragments of this vector containing the recombinant genes were microinjected. The embryos were then transferred to the oviduct of hormonally prepared adoptive females. About 10% of the manipulated embryos gave birth to mice and 2-5% of the embryos handled to transgenic mice. The presence of the transgenes was revealed by the technique of Southern transfer from DNA extracted from the tails of mice. Growth hormone concentrations in the blood and milk of animals were assessed using specific radioimmunological tests.

L'activité biologique de l'hGH a été évaluée en ajoutant du lait au milieu de culture de cellules ou d'explants mammaires de lapin. L'hGH contenue dans le lait a induit l'expression du gène de la caséine-β évaluée par la mesure des ARNm et de la protéine.The biological activity of hGH was evaluated by adding milk to the culture medium of rabbit breast cells or explants. The hGH contained in milk induced the expression of the casein-β gene evaluated by measuring the mRNA and the protein.

EXEMPLE 4EXAMPLE 4 :: PRODUCTION D'HORMONE DE CROISSANCE HUMAINE OU BOVINE DANS LE LAIT DE SOURIS TRANSGENIQUES AYANT INCORPORE LES CONSTRUCTIONS pW3 ET pJ4PRODUCTION OF HUMAN OR BOVINE GROWTH HORMONE IN TRANSGENIC MOUSE MILK HAVING THE CONSTRUCTIONS pW3 AND pJ4

Les concentrations d'hormones ont été déterminées par des tests radioimmunologiques spécifiques.The hormone concentrations were determined by specific radioimmunological tests.

L'identification de l'hGH dans le lait d'une souris transgénique est réalisée de la façon suivante. Le lait de souris est centrifugé à 150.000g pendant une heure pour sédimenter les micelles de caséine. Le surnageant (1 µl par puits) a été récupéré et examiné par une électrophorèse en gel de polyacrylamide, en présence d'hormone de croissance humaine témoin et d'un lait contrôle. Les résultats sont rapportés sur la figure 4.The identification of hGH in the milk of a transgenic mouse is carried out as follows. The mouse milk is centrifuged at 150,000 g for one hour to sediment the casein micelles. The supernatant (1 μl per well) was collected and examined by polyacrylamide gel electrophoresis, in the presence of control human growth hormone and a control milk. The results are reported in Figure 4.

Les animaux ayant intégré la construction pW₃ donnent des concentrations d'hGH de l'ordre de 10 mg/ml de lait et peuvent atteindre 21 mg/ml.Animals which have integrated the pW₃ construct give hGH concentrations of the order of 10 mg / ml of milk and can reach 21 mg / ml.

Les animaux ayant intégré la construction pJ₄ produisent de l'ordre de 5 mg/ml de lait de bGH et jusqu'à 17 mg/ml.The animals having integrated the pJ₄ construct produce about 5 mg / ml of bGH milk and up to 17 mg / ml.

Le procédé selon la présente invention permet de récolter 1,5 ml de lait/glande mammaire de souris (en mettant la glande mammaire dans la glace). 200 souris allaitantes exprimant une protéine étrangère à la concentration de 3 - 5 mg/ml fournissent donc 1 g de la protéine brute.The method according to the present invention makes it possible to collect 1.5 ml of milk / mammary gland of mice (by putting the mammary gland in ice). 200 lactating mice expressing a foreign protein at a concentration of 3 - 5 mg / ml therefore provide 1 g of the crude protein.

EXEMPLE 5EXAMPLE 5 :: CONSTRUCTIONS DE GENEGENE CONSTRUCTIONS

Les constructions des gènes utilisés pour exprimer des protéines recombinantes dans le lait d'animaux transgèniques contiennent dans tous les cas la région régulatrice du gène WAP de lapin : fragment BamHl-HindIII (6,3 Kb) ou fragment EcoRl-HindIII (17,6 Kb). Les plasmides WAP-hGH, WAP bGH, WAPα-AT, et WAP-EPO contiennent respectivement les gènes entiers (séquence de tête, exons, introns et terminateur de transcription) de l'hormone de croissance humaine (hGH), de l'hormone de croissance bovine (bGH), de l'αl-antitrypsine humaine mutée en Arg358 et d'érythropoeïtine humaine. Dans ces constructions les gènes ont été associés à la région régulatrice du gène WAP au site HindIII. La construction WAP-FVIII-ΔII contient l'ADNc du facteur VIII humain dans sa forme ΔII précédée d'un intron du gène du facteur VIII humain. Cet ensemble intron-ADNc a été introduit dans le site HindIII du gène WAP de lapin entier (figure 6).The gene constructs used to express recombinant proteins in the milk of transgenic animals contain in all cases the regulatory region of the rabbit WAP gene: BamHI-HindIII fragment (6.3 Kb) or EcoRI-HindIII fragment (17.6 Kb). The plasmids WAP-hGH, WAP bGH, WAPα-AT, and WAP-EPO respectively contain the whole genes (leader sequence, exons, introns and transcription terminator) of the human growth hormone (hGH), of the hormone of bovine growth (bGH), human α l -antitrypsin mutated to Arg358 and human erythropoeitin. In these constructions, the genes were associated with the regulatory region of the WAP gene at the HindIII site. The WAP-FVIII-ΔII construct contains the human factor VIII cDNA in its ΔII form preceded by an intron of the human factor VIII gene. This intron-cDNA set was introduced into the HindIII site of the entire rabbit WAP gene (FIG. 6).

EXEMPLE 6EXAMPLE 6 :: IDENTIFICATION DE L'ACTIVITE DE LA REGION REGULATRICE DU GENE WAP DE LAPIN IN VITROIDENTIFICATION OF THE ACTIVITY OF THE REGULATORY REGION OF THE WAP GENE OF RABBIT IN VITRO

Des longueurs variables de la région située en amont du site d'initiation de la transcription du gène WAP ont été associées à un gène rapporteur (le gène CAT : chloramphenicol acetyl transferase) (figure 7). Ces constructions ont été introduites dans des cellules épithéliales mammaires cultivées sur un gel de collagène I de queue de rat par une transfection à l'aide de lipofectine. Les cellules ont ensuite été maintenues pendant trois jours en présence d'hormones (insuline, cortisol, prolactine). L'enzyme a alors été mesurée dans les extraits cellulaires. Les constructions ne contenant que 1806 pb ou moins de la région régulatrice n'expriment pas le gène CAT. La construction contenant 3000 bp est faiblement active, tandis que les constructions contenant 6300 et 17600 bp sont franchement exprimées en présence des hormones. La prolactine seule exerce un rôle inducteur faible mais significatif sur le gène CAT. L'insuline et surtout le cortisol, inactifs seuls, amplifient l'action de la prolactine. La sensibilité du gène vis-à-vis des hormones est exactement identique à celle du gène WAP endogène des cellules. Les régions -3000-1806 bp et -6300-3000 bp contiennent donc des éléments régulateurs essentiels pour que le gène WAP s'exprime de manière intense (figure 8). Le fragment 17600-6300 bp n'apporte pas de stimulation supplémentaire in vitro ce qui n'exclut pas qu'il puisse avoir une telle action in vitro chez les animaux transgèniques. Ces expériences révèlent pour la première fois l'activité des régions régulatrices du gène WAP in vitro par des transfections des cellules.Variable lengths of the region upstream of the WAP gene transcription initiation site have been associated with a reporter gene (the CAT gene: chloramphenicol acetyl transferase) (Figure 7). These constructs were introduced into mammary epithelial cells cultured on a rat tail collagen I gel by a transfection using lipofectin. The cells were then maintained for three days in the presence of hormones (insulin, cortisol, prolactin). The enzyme was then measured in the cell extracts. Constructs containing only 1806 bp or less of the regulatory region do not express the CAT gene. The construct containing 3000 bp is weakly active, while the constructs containing 6300 and 17600 bp are frankly expressed in the presence of hormones. Prolactin alone exerts a weak but significant inducing role on the CAT gene. Insulin and especially cortisol, inactive alone, amplify the action of prolactin. The sensitivity of the gene to hormones is exactly the same as that of the endogenous WAP gene in cells. The -3000-1806 bp and -6300-3000 bp regions therefore contain essential regulatory elements for the WAP gene to be expressed in an intense manner (FIG. 8). The 17600-6300 bp fragment does not provide additional stimulation in vitro, which does not exclude that it can have such an action in vitro in transgenic animals. These experiments reveal for the first time the activity of the regulatory regions of the WAP gene in vitro by cell transfections.

REFERENCESREFERENCES

  • 1. VAN BRUNT J. Biotechnology (1988) 6, 1149-11541. VAN BRUNT J. Biotechnology (1988) 6, 1149-1154
  • 2. SIMONS J.P. et al. Nature (1987) 328, 530-5322. SIMONS J.P. et al. Nature (1987) 328, 530-532
  • 3. SIMONS J.P. et al. Biotechnology (1988) 6, 179-1833. SIMONS J.P. et al. Biotechnology (1988) 6, 179-183
  • 4. CLARK A.J. Biotechnology (1989) 7, 487-4924. CLARK A.J. Biotechnology (1989) 7, 487-492
  • 5. ARCHIBALD A.L. et al. Proc. Natl. Acad. Sci. USA (1990) 87, 5178-51825. ARCHIBALD A.L. et al. Proc. Natl. Acad. Sci. USA (1990) 87, 5178-5182
  • 6. HARRIS et al. J. Reprod. Fert. (1990) 88, 707-7156. HARRIS et al. J. Reprod. Fer. (1990) 88, 707-715
  • 7. GORDON K. et al. Biotechnology (1987) 5, 1183-11877. GORDON K. et al. Biotechnology (1987) 5, 1183-1187
  • 8. PITTIUS C.W. Proc. Natl. Acad. Sci. USA (1988) 85, 5874-58788. PITTIUS C.W. Proc. Natl. Acad. Sci. USA (1988) 85, 5874-5878
  • 9. PITTIUS C.W. et al. Mol. Endocr. (1988) 2, 1027-10329. PITTIUS C.W. et al. Mol. Endocr. (1988) 2, 1027-1032
  • 10. YU S.H. et al. Mol. Biol. Med. (1989) 6, 255-26110. YU S.H. et al. Mol. Biol. Med. (1989) 6, 255-261
  • 11. LEE K.F. Nucleic Acids Res. (1989) 16, 1027-104011. LEE K.F. Nucleic Acids Res. (1989) 16, 1027-1040
  • 12. MEADE H. Biotechnology (1990) 8, 443-44612. MEADE H. Biotechnology (1990) 8, 443-446
  • 13. BUHLER T.A. Biotechnology (1990) 8, 140-14313. BUHLER T.A. Biotechnology (1990) 8, 140-143
  • 14. VILOTTE J.L. Em. J. Biochem. (1989) 186, 43-4814. VILOTTE J.L. Em. J. Biochem. (1989) 186, 43-48
  • 15. BAYNA E.M. et al. Nucleic Acids Res. (1990) 18, 2977-298515. BAYNA E.M. et al. Nucleic Acids Res. (1990) 18, 2977-2985
  • 16. LEE K.F. et al. Mol. Cell Biol. (1989) 9, 560-56516. LEE K.F. et al. Mol. Cell Biol. (1989) 9, 560-565
  • 17. GRABOWSKI H. et al. (Soumis à publication)17. GRABOWSKI H. et al. (Subject to publication)
  • 18. DEVINOY E. et al. Nucleic Acids Res. (1988) 16, 1181418. DEVINOY E. et al. Nucleic Acids Res. (1988) 16, 11814
  • 19. THEPOT D. et al. Nucleic Acids Res. (1990) 18, 364119. THEPOT D. et al. Nucleic Acids Res. (1990) 18, 3641
  • 20. GUNZBURG W.H. et al. Molecular Endocrinology (1991). A Mammary-specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia cells in Transgenic Mice.20. GUNZBURG W.H. et al. Molecular Endocrinology (1991). A Mammary-specific Promoter Directs Expression of Growth Hormone not only to the Mammary Gland, but also to Bergman Glia cells in Transgenic Mice.
  • 21. HENNIGHAUSEN L. Protein Expression and Purification (1990) 1, 3-821. HENNIGHAUSEN L. Protein Expression and Purification (1990) 1, 3-8
  • 22. BURDON T. et al. Expression of a whey acidic protein transgene during mammary development:Evidence for different mechanisms of regulation during pregnancy and lactation22. BURDON T. et al. Expression of a whey acidic protein transgene during mammary development: Evidence for different mechanisms of regulation during pregnancy and lactation
  • 23. REDDY B.V. et al. Human Growth Hormone Expression in Transgenic Mouse Milk, abstract in Transgenes, Development and Disease. p21223. REDDY B.V. et al. Human Growth Hormone Expression in Transgenic Mouse Milk, abstract in Transgenes, Development and Disease. p212
  • 24. MASCHIO A. et al. (1991) Biochem. J. 275 454-46724. MASCHIO A. et al. (1991) Biochem. J. 275 454-467
LEGENDE RELATIVE AUX FIGURESLEGEND RELATING TO FIGURES FIGURE 6 : FIGURE 6 :

Les constructions utilisées pour obtenir l'expression de protéines recombinantes dans le lait d'animaux transgéniques.The constructs used to obtain the expression of recombinant proteins in the milk of transgenic animals.

FIGURE 7 : FIGURE 7 :

Schéma des différentes constructions comportant le gène CAT placé sous la dépendance de longueurs variables du gène de la WAP de lapin.Diagram of the various constructions comprising the CAT gene placed under the dependence of variable lengths of the rabbit WAP gene.

FIGURE 8 : FIGURE 8 :

Représentation de la variation de l'activité CAT dans des extraits de cellules épithéliales primaires mammaires de lapin transfectées par différents plasmides.Representation of the variation in CAT activity in extracts of primary rabbit mammary epithelial cells transfected with different plasmids.

Claims (20)

Procédé de préparation d'une protéine hétérologue d'intérêt sous forme mature ou sous forme fusionnée dans le lait d'une femelle de mammifère, procédé dans lequel : - on élève ladite femelle et, - on récupère le lait d'où l'on récupère ladite protéine que l'on sépare si nécessaire, caractérisé en ce que ladite femelle est un animal transgénique dans le génome duquel a été intégrée une séquence codant pour ladite protéine d'intérêt sous le contrôle d'au moins une séquence figurant parmi les éléments d'expression de la protéine WAP de lapin et se trouvant sur le fragment d'une longueur d'au moins 3 Kb à partir de l'extrémité 3′ du promoteur WAP complet.Process for the preparation of a heterologous protein of interest in mature form or in fused form in the milk of a mammalian female, process in which: - said female is raised and, the milk is recovered from which the said protein is recovered which is separated if necessary, characterized in that said female is a transgenic animal into the genome of which a sequence coding for said protein of interest has been integrated under the control of at least one sequence appearing among the expression elements of the rabbit WAP protein and is found on the fragment at least 3 Kb in length from the 3 ′ end of the full WAP promoter. Procédé selon la revendication 1, caractérisé en ce que la séquence codant pour ladite protéine hétérologue d'intérêt est sous le contrôle d'une séquence comportant en outre au moins un élément d'expression situé sur le fragment compris entre 3 Kb et 6,3 Kb à partir de l'extrémité 3′ du promoteur WAP de lapin complet.Method according to claim 1, characterized in that the sequence coding for said heterologous protein of interest is under the control of a sequence further comprising at least one expression element located on the fragment of between 3 Kb and 6.3 Kb from the 3 ′ end of the complete rabbit WAP promoter. Procédé selon l'une des revendications 1 et 2, caractérisé en ce que la séquence codant pour ladite protéine hétérologue d'intérêt est sous le contrôle d'une séquence comprenant tous les éléments d'expression situés sur le fragment d'une longueur de 6,3 Kb à partir de l'extrémité 3′ du promoteur WAP de lapin complet.Method according to either of Claims 1 and 2, characterized in that the sequence coding for the said heterologous protein of interest is under the control of a sequence comprising all the expression elements situated on the fragment with a length of 6 , 3 Kb from the 3 ′ end of the complete rabbit WAP promoter. Procédé selon la revendication 3, caractérisé en ce que la séquence du promoteur WAP comporte les éléments d'expression situés sur la séquence de 6,3 Kb comprise entre les sites HindIII et BamHI représentés sur la figure 1.Method according to claim 3, characterized in that the sequence of the WAP promoter comprises the expression elements located on the 6.3 Kb sequence included between the HindIII and BamHI sites represented in FIG. 1. Procédé selon l'une des revendications 1 à 4, caractérisé en ce que la séquence codant pour ladite protéine hétérologue d'intérêt est sous le contrôle d'une séquence comprenant tous les éléments d'expression situés sur le fragment d'une longueur de 17 Kb, à partir de l'extrémité 3′ du promoteur WAP de lapin complet.Method according to one of claims 1 to 4, characterized in that the sequence coding for said heterologous protein of interest is under the control of a sequence comprising all the expression elements situated on the fragment with a length of 17 Kb, from the 3 ′ end of the complete rabbit WAP promoter. Procédé selon la revendication 5, caractérisé en ce que la séquence du promoteur WAP comporte les éléments d'expression situés sur la séquence de 17 Kb, comprise entre les sites HindIII et EcoRI représentés sur la figure 1.Method according to claim 5, characterized in that the sequence of the WAP promoter comprises the expression elements located on the 17 Kb sequence, between the HindIII and EcoRI sites represented in FIG. 1. Procédé selon l'une des revendications 1 à 6, caractérisé en ce que la séquence codant pour ladite protéine d'intérêt est précédée vers son extrémité 5′, d'une séquence correspondant au promoteur du gène WAP de lapin complet, ou d'une séquence équivalente assurant la fonction de promoteur.Method according to one of claims 1 to 6, characterized in that the sequence coding for said protein of interest is preceded towards its 5 ′ end, by a sequence corresponding to the promoter of the complete rabbit WAP gene, or by a equivalent sequence ensuring the function of promoter. Procédé selon l'une des revendications 1 à 7, caractérisé en ce que ladite protéine d'intérêt est précédée de la totalité du gène WAP et du promoteur WAP dudit gène ou d'une séquence équivalente.Method according to one of claims 1 to 7, characterized in that said protein of interest is preceded by the whole of the WAP gene and the WAP promoter of said gene or an equivalent sequence. Procédé selon la revendication 8, caractérisé en ce que, dans la séquence correspondant au gène de la protéine WAP de lapin, le codon AUG initiateur est délété.Method according to claim 8, characterized in that, in the sequence corresponding to the gene for the rabbit WAP protein, the initiator AUG codon is deleted. Procédé selon l'une des revendications 1 à 9, caractérisé en ce que dans la séquence correspondant à la séquence codant pour la protéine hétérologue, le codon AUG initiateur est délété.Method according to one of claims 1 to 9, characterized in that in the sequence corresponding to the sequence coding for the heterologous protein, the initiator AUG codon is deleted. Procédé selon l'une des revendications 1 à 10, caractérisé en ce que pour récupérer la protéine d'intérêt dans le lait de ladite femelle de mammifère, a) on recueille les glandes mammaires, b) on laisse incuber les glandes mammaires à une température d'environ 0°C pendant une durée variant de deux heures à 18 heures, c) on récupère le lait ayant spontanément exsudé des glandes, d) on isole la protéine d'intérêt à partir du lait et on obtient ladite protéine purifiée. Method according to one of claims 1 to 10, characterized in that to recover the protein of interest in the milk of said mammalian female, a) the mammary glands are collected, b) the mammary glands are incubated at a temperature of approximately 0 ° C. for a period varying from two hours to 18 hours, c) the milk having spontaneously exuded from the glands is recovered, d) the protein of interest is isolated from milk and said purified protein is obtained. Procédé selon l'une des revendications 1 à 11, caractérisé en ce que la séquence codant pour la protéine hétérologue est la séquence codant pour l'hormone de croissance humaine.Method according to one of claims 1 to 11, characterized in that the sequence coding for the heterologous protein is the sequence coding for human growth hormone. Procédé selon l'une des revendications 1 à 12, caractérisé en ce que la protéine hétérologue est choisie parmi : - les facteurs de croissance, - les interleukines, - les facteurs de stimulation, - les kinases, - les facteurs de coagulation, - l'alpha-antitrypsine, - l'hirudine. Method according to one of claims 1 to 12, characterized in that the heterologous protein is chosen from: - growth factors, - interleukins, - stimulating factors, - kinases, - coagulation factors, - alpha-antitrypsin, - hirudin. Procédé selon la revendication 13, caractérisé en ce que la protéine est choisie parmi : - l'érythropoïétine, - le G-CSF, - l'alpha-antitrypsine, - l'urokinase - le facteur VIII. Method according to claim 13, characterized in that the protein is chosen from: - erythropoietin, - the G-CSF, - alpha-antitrypsin, - urokinase - factor VIII. Procédé selon la revendication 14, caractérisé en ce que la séquence codant pour la protéine d'intérêt, est constituée par l'ADNc du facteur VIII- deltaII humain, précédé du premier intron du gène du facteur VIII.Process according to Claim 14, characterized in that the sequence coding for the protein of interest, consists of the cDNA of human factor VIII-deltaII, preceded by the first intron of the factor VIII gene. Lait ou produit du lait contenant une protéine d'intérêt obtenue par la mise en oeuvre du procédé selon l'une des revendications 1 à 15.Milk or milk product containing a protein of interest obtained by the implementation of the method according to one of claims 1 to 15. Cellule eucaryote, caractérisée en ce qu'elle contient dans son génome une séquence codant pour la protéine d'intérêt hétérologue, sous le contrôle du promoteur WAP de lapin ou d'une séquence équivalente assurant la fonction de promoteur.Eukaryotic cell, characterized in that it contains in its genome a sequence coding for the heterologous protein of interest, under the control of the rabbit WAP promoter or an equivalent sequence ensuring the function of promoter. Cellule eucaryote selon la revendication 17, caractérisée en ce qu'il s'agit d'une cellule épithéliale primaire mammaire d'un mammifère femelle.Eukaryotic cell according to claim 17, characterized in that it is a primary mammary epithelial cell of a female mammal. Animal transgénique, caractérisé en ce qu'il renferme des cellules selon l'une des revendications 17 et 18.Transgenic animal, characterized in that it contains cells according to one of claims 17 and 18. Séquence d'ADN, caractérisée en ce qu'elle comporte au moins un gène hétérologue codant pour une protéine d'intérêt, sous le contrôle d'au moins une séquence figurant parmi les éléments d'expression de la protéine WAP de lapin et se trouvant sur le fragment d'une longueur d'au moins 3 Kb à partir de l'extrémité 3′ du promoteur WAP complet.DNA sequence, characterized in that it comprises at least one heterologous gene coding for a protein of interest, under the control of at least one sequence appearing among the expression elements of the rabbit WAP protein and found on the fragment at least 3 Kb in length from the 3 ′ end of the full WAP promoter.
EP92401635A 1991-06-12 1992-06-12 Production of protein of interest in the milk of transgenic mammal Expired - Lifetime EP0527063B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9107179A FR2677652B1 (en) 1991-06-12 1991-06-12 PROCESS FOR PREPARING A PROTEIN OF INTEREST IN MILK OF A TRANSGENIC ANIMAL, PRODUCT OBTAINED, AND EUCARYOTIC CELL USED
FR9107179 1991-06-12

Publications (2)

Publication Number Publication Date
EP0527063A1 true EP0527063A1 (en) 1993-02-10
EP0527063B1 EP0527063B1 (en) 2003-08-27

Family

ID=9413760

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92401635A Expired - Lifetime EP0527063B1 (en) 1991-06-12 1992-06-12 Production of protein of interest in the milk of transgenic mammal

Country Status (10)

Country Link
EP (1) EP0527063B1 (en)
JP (1) JP3824632B2 (en)
AT (1) ATE248221T1 (en)
CA (1) CA2111238C (en)
DE (1) DE69233173T2 (en)
DK (1) DK0527063T3 (en)
ES (1) ES2206444T3 (en)
FR (1) FR2677652B1 (en)
PT (1) PT527063E (en)
WO (1) WO1992022644A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019935A1 (en) * 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
WO2010076768A1 (en) 2008-12-31 2010-07-08 Lfb Biotechnologies Isolated peptides of rabbit factor vii
WO2010094900A1 (en) 2009-02-19 2010-08-26 Lfb Biotechnologies Means for purifying a coagulation protein, and methods for implementing same
WO2010094899A1 (en) 2009-02-19 2010-08-26 Lfb Biotechnologies Nucleic acids specifically binding with human factor vii/viia and uses thereof
WO2011012831A1 (en) 2009-07-31 2011-02-03 Lfb Biotechnologies Method for purifying active gla-domain coagulation proteins
WO2011012830A1 (en) 2009-07-31 2011-02-03 Lfb Biotechnologies Method for purifying gla-domain coagulation proteins
WO2011125034A1 (en) 2010-04-09 2011-10-13 Bioprotein Technologies Sa Preparation of recombinant human plasma phospholipid transfer protein (pltp) from the milk of transgenic animals
EP2508533A1 (en) 2007-08-14 2012-10-10 LFB Biotechnologies Process for the selection of an aptamer
US8435940B2 (en) 2006-01-05 2013-05-07 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2013080134A2 (en) 2011-11-28 2013-06-06 Lfb Biotechnologies Anti-fh aptamers, method for producing same, and uses thereof
US8492524B2 (en) 2006-12-29 2013-07-23 Lfb Biotechnologies Method for extracting a protein from milk
EP2687595A1 (en) 2012-07-19 2014-01-22 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
FR3006591A1 (en) * 2013-06-11 2014-12-12 Lab Francais Du Fractionnement FACTOR VII COMPOSITION HAVING A SUBSTANTIALLY HOMOGENEOUS ISOELECTRIC POINT
WO2015044923A2 (en) 2013-09-30 2015-04-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nucleic acids binding specifically to human factor ix/ixa, and uses thereof
US10172909B2 (en) 2010-12-15 2019-01-08 The University Of Utah Research Foundation Neuropeptide analogs, compositions, and methods for treating pain
US10364425B2 (en) 2006-05-31 2019-07-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units
WO2019239080A1 (en) 2018-06-14 2019-12-19 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of factor vii and an anti-factor ix/x bispecific antibody

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5627268A (en) * 1994-06-07 1997-05-06 Dnx Biotherapeutics Hemoglobin comprising globin fusion proteins
US5821351A (en) * 1994-06-10 1998-10-13 Dnx Biotherapeutics Production of hemoglobin having a delta-like globin
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US5907080A (en) * 1995-11-30 1999-05-25 Nexia Biotechnologies, Inc. Method for development of transgenic dwarf goats
EP1194570A1 (en) 1999-06-23 2002-04-10 PPL Therapeutics (Scotland) Limited Fusion proteins incorporating lysozyme
EP2138583A1 (en) * 2000-12-22 2009-12-30 Institut National De La Recherche Agronomique Position-independent and tissue specific expression of a transgene in milk of transgenic animals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1991003551A1 (en) * 1989-09-11 1991-03-21 Tsi-Mason Research Institute Production of growth hormone in transgenic animal milk
EP0264166B1 (en) * 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264166B1 (en) * 1986-04-09 1996-08-21 Genzyme Corporation Transgenic animals secreting desired proteins into milk
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1991003551A1 (en) * 1989-09-11 1991-03-21 Tsi-Mason Research Institute Production of growth hormone in transgenic animal milk

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY, vol. 8, Février 1990, NEW YORK (US) pages 140-143; BÜHLER, T.A. et al.: "Rabbit beta-casein promoter directs secretion of human interleukin-2 into the milk of transgenic rabbits" *
CELL BIOLOGY INTERNATIONAL REPORTS, vol. 15, no. 2, Février 1991, pages 121-129; PUISSANT, C. et HOUDEBINE, L.M.: "Cortisol induces rapid accumulation of Whey Acid Protein mRNA but not of asl and b-casein mRNA in rabbit mammary explants" *
NUCLEIC ACIDS RESEARCH, vol. 16, no. 16, 25 Aout 1988, ARLINGTON, VIRGINIA (US) page 8180; DEVINOY, E. et al.: "Sequence of the rabbit whey acid protein cDNA" *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 84, Mars 1987, WASHINGTON (US) pages 1299-1303; ANDRES, A.C. et al.: "Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice" *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693436B2 (en) * 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
WO1994019935A1 (en) * 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
US9586999B2 (en) 2006-01-05 2017-03-07 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
US8435940B2 (en) 2006-01-05 2013-05-07 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
US8933020B2 (en) 2006-01-05 2015-01-13 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
US10364425B2 (en) 2006-05-31 2019-07-30 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units
US8492524B2 (en) 2006-12-29 2013-07-23 Lfb Biotechnologies Method for extracting a protein from milk
EP2508533A1 (en) 2007-08-14 2012-10-10 LFB Biotechnologies Process for the selection of an aptamer
WO2010076768A1 (en) 2008-12-31 2010-07-08 Lfb Biotechnologies Isolated peptides of rabbit factor vii
WO2010094900A1 (en) 2009-02-19 2010-08-26 Lfb Biotechnologies Means for purifying a coagulation protein, and methods for implementing same
WO2010094899A1 (en) 2009-02-19 2010-08-26 Lfb Biotechnologies Nucleic acids specifically binding with human factor vii/viia and uses thereof
WO2011012830A1 (en) 2009-07-31 2011-02-03 Lfb Biotechnologies Method for purifying gla-domain coagulation proteins
WO2011012831A1 (en) 2009-07-31 2011-02-03 Lfb Biotechnologies Method for purifying active gla-domain coagulation proteins
WO2011125034A1 (en) 2010-04-09 2011-10-13 Bioprotein Technologies Sa Preparation of recombinant human plasma phospholipid transfer protein (pltp) from the milk of transgenic animals
US10172909B2 (en) 2010-12-15 2019-01-08 The University Of Utah Research Foundation Neuropeptide analogs, compositions, and methods for treating pain
WO2013080134A2 (en) 2011-11-28 2013-06-06 Lfb Biotechnologies Anti-fh aptamers, method for producing same, and uses thereof
EP2687595A1 (en) 2012-07-19 2014-01-22 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US9982247B2 (en) 2012-07-19 2018-05-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for purifying transgenic factor VII/VIIA
WO2014013024A1 (en) 2012-07-19 2014-01-23 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for purifying transgenic factor vii
FR3006591A1 (en) * 2013-06-11 2014-12-12 Lab Francais Du Fractionnement FACTOR VII COMPOSITION HAVING A SUBSTANTIALLY HOMOGENEOUS ISOELECTRIC POINT
WO2014198735A1 (en) * 2013-06-11 2014-12-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Transgenic factor vii having a specific n-glycosylation and substantially homogenous isoelectric point
US10683492B2 (en) 2013-06-11 2020-06-16 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Transgenic factor VII having a specific N-glycosylation and substantially homogenous isoelectric point
US11254920B2 (en) 2013-06-11 2022-02-22 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Factor VII composition having a substantially homogenous isoelectric point
WO2015044923A2 (en) 2013-09-30 2015-04-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nucleic acids binding specifically to human factor ix/ixa, and uses thereof
WO2019239080A1 (en) 2018-06-14 2019-12-19 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of factor vii and an anti-factor ix/x bispecific antibody

Also Published As

Publication number Publication date
DE69233173T2 (en) 2004-05-27
ATE248221T1 (en) 2003-09-15
EP0527063B1 (en) 2003-08-27
ES2206444T3 (en) 2004-05-16
CA2111238C (en) 2006-08-29
JPH06508515A (en) 1994-09-29
FR2677652B1 (en) 2005-05-27
JP3824632B2 (en) 2006-09-20
DK0527063T3 (en) 2003-12-22
WO1992022644A1 (en) 1992-12-23
PT527063E (en) 2004-01-30
FR2677652A1 (en) 1992-12-18
CA2111238A1 (en) 1992-12-23
DE69233173D1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
EP0527063B1 (en) Production of protein of interest in the milk of transgenic mammal
US5573933A (en) Transgenic pigs
RU2085587C1 (en) Method of transgenic sheep producing
US4873316A (en) Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4870009A (en) Method of obtaining gene product through the generation of transgenic animals
JPH06506105A (en) Homologous recombination in mammalian cells
US5648243A (en) Human serum albumin expression construct
EP0599978A1 (en) Gene encoding a human beta-casein process for obtaining the protein and use thereof in an infant formula
DE69434622T2 (en) VARIATIONS OF BIT ACID STIMULATED LIPASE, DNA THAT CODES, AND TRANSGENIC NON-HUMAN MAMMALS
Sokolov et al. Tissue-and development-specific expression in transgenic mice of a type I procollagen (COL1A1) minigene construct with 2.3 kb of the promoter region and 2 kb of the 3'-flanking region. Specificity is independent of the putative regulatory sequences in the first intron
US5965788A (en) Transgenic non-human mammal comprising a rabbit WAP promoter
US6268545B1 (en) Transgenic non-human mammal comprising a rabbit WAP promoter, uses thereof, and a DNA construct comprising the rabbit WAP promoter
EP0771874B1 (en) Transgenic protein production
DE60037397T2 (en) EXPRESSION OF DERIVED, HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS
EP0309559B1 (en) Method for producing transgenic pigs
JPH10502816A (en) α-lactalbumin gene construct
US7053262B2 (en) Mammary gland tissue-specific expression system using β-casein promoter site of Korean native goat
DE60314017T2 (en) CHIMERIC PROTEIN CONTAINS THE CYSTEIN PROTEASE FROM THE LARGE LIVERGEL FUSIONED TO THE HEPATITIS B CORE PROTEIN OR UBIQUITIN; PLANTS EXPRESSING THIS PROTEIN, AND THEIR USE AS VACCINE
US6018039A (en) MC26 gene expression-regulatory region
US20050043530A1 (en) Seminal vesicle tissue-specific promoters and uses thereof
DEYKIN et al. RESEARCH RESULTS IN PHARMACOLOGY
WO2010125872A1 (en) Transgenic goldfish
JP2005211079A (en) NEW METHOD FOR PRODUCING SUBSTANCE IN TRANSGENIC ANIMAL MAMMARY GLAND BY USING mC26 GENE MANIFESTATION CONTROL REGION
JPH07194380A (en) New method for producing substance in trans-genic animal mammary gland by using mc26 gene manifestation control range
JP2006217919A (en) New method for producing substance in transgenic animal mammary gland by using mc26 gene expression control region

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19930809

17Q First examination report despatched

Effective date: 19951222

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/00 A, 7C 12N 15/85 B, 7C 12N 15/18 B, 7C 12N 5/10 B, 7A 01K 67/027 B, 7C 12N 15/12 B, 7C 07K 14/00 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/00 A, 7C 12N 15/85 B, 7C 12N 15/18 B, 7C 12N 5/10 B, 7A 01K 67/027 B, 7C 12N 15/12 B, 7C 07K 14/00 B

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69233173

Country of ref document: DE

Date of ref document: 20031002

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MOINAS & SAVOYE SA

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030404683

Country of ref document: GR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20031217

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2206444

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110621

Year of fee payment: 20

Ref country code: MC

Payment date: 20110622

Year of fee payment: 20

Ref country code: SE

Payment date: 20110620

Year of fee payment: 20

Ref country code: LU

Payment date: 20110624

Year of fee payment: 20

Ref country code: GR

Payment date: 20110624

Year of fee payment: 20

Ref country code: PT

Payment date: 20110531

Year of fee payment: 20

Ref country code: CH

Payment date: 20110616

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110627

Year of fee payment: 20

Ref country code: GB

Payment date: 20110627

Year of fee payment: 20

Ref country code: DK

Payment date: 20110621

Year of fee payment: 20

Ref country code: AT

Payment date: 20110621

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20110624

Year of fee payment: 20

Ref country code: DE

Payment date: 20110613

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20110726

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110629

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233173

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69233173

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20120612

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20120612

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

BE20 Be: patent expired

Owner name: INSTITUT NATIONAL DE LA RECHERCHE *AGRONOMIQUE

Effective date: 20120612

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20120611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120613

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120621

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120611

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20030404683

Country of ref document: GR

Effective date: 20120613

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 248221

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120612

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20120613